• Thu, January 23, 2025

by: MSN

Avidity Biosciences CFO sells $93,985 in stock

Michael F. MacLean, Chief Financial Officer of Avidity Biosciences, Inc. (NASDAQ:RNA), recently sold shares of the company stock valued at approximately $93,985. The transactions occurred on January 21,

by: MSN

2 'Strong Buy'-Rated Dividend Stocks With Yields Above 7% for 2025

Investing in dividend stocks with a high yield of more than 7% can significantly boost your portfolio's income potential, especially in a low-interest-rate environment. However, targeting companies with sustainable dividend payouts is crucial,

by: MSN

Altimmune's SWOT analysis: pemvidutide potential drives stock outlook

Altimmune, Inc. (NASDAQ:ALT), a biopharmaceutical company with a market capitalization of $503.56 million focused on developing treatments for liver disease and obesity, has been garnering attention from analysts and investors alike.
  • Fri, January 24, 2025

by: WOPRAI

Richard Hightower Maintained (MAA) at Equal with Decreased Target to $152 on, Jan 24th, 2025

by: WOPRAI

Adam Kramer Upgraded (MAA) to Overweight and Increased Target to $168 on, Jan 24th, 2025

by: WOPRAI

Arvind Ramnani Maintained (MA) at Overweight with Increased Target to $591 on, Jan 24th, 2025

by: WOPRAI

Paul Lejuez Reinstated (KR) to Neutral and Held Target at $61 on, Jan 24th, 2025

by: WOPRAI

Matthew Smith Maintained (KHC) at Hold with Decreased Target to $32 on, Jan 24th, 2025

by: WOPRAI

Nathan Jones Maintained (ITW) at Hold with Decreased Target to $266 on, Jan 24th, 2025

by: WOPRAI

Nathan Jones Maintained (ITT) at Buy with Decreased Target to $179 on, Jan 24th, 2025

by: WOPRAI

Richard Newitter Maintained (ISRG) at Buy with Increased Target to $666 on, Jan 24th, 2025

by: WOPRAI

Joanne Wuensch Maintained (ISRG) at Buy with Increased Target to $711 on, Jan 24th, 2025

by: WOPRAI

Richard Hightower Maintained (IRT) at Equal with Decreased Target to $21 on, Jan 24th, 2025

by: WOPRAI

Nathan Jones Maintained (IR) at Hold with Decreased Target to $100 on, Jan 24th, 2025

by: WOPRAI

Julien Roch Upgraded (IPG) to Overweight and Increased Target to $36 on, Jan 24th, 2025

by: WOPRAI

Adam Kramer Downgraded (INVH) to Equal and Decreased Target to $35 on, Jan 24th, 2025

by: WOPRAI

Matthew Smith Maintained (HSY) at Hold with Decreased Target to $170 on, Jan 24th, 2025

by: WOPRAI

Matthew Smith Maintained (HAIN) at Hold with Decreased Target to $7 on, Jan 24th, 2025

by: WOPRAI

Gil Luria Maintained (GOOGL) at Neutral with Increased Target to $200 on, Jan 24th, 2025

by: WOPRAI

Matthew Smith Maintained (GIS) at Buy with Decreased Target to $72 on, Jan 24th, 2025

by: WOPRAI

Matthew Akers Maintained (GE) at Overweight with Increased Target to $250 on, Jan 24th, 2025

by: WOPRAI

Ken Herbert Maintained (GE) at Outperform with Increased Target to $220 on, Jan 24th, 2025

by: WOPRAI

Terry McEvoy Reiterated (FMBH) at Equal and Held Target at $43 on, Jan 24th, 2025

by: WOPRAI

Nathan Jones Maintained (FLS) at Buy with Increased Target to $75 on, Jan 24th, 2025

by: WOPRAI

Brian Brophy Maintained (FIX) at Buy with Increased Target to $577 on, Jan 24th, 2025

by: WOPRAI

Orest Wowkodaw Maintained (FCX) at Sector with Decreased Target to $45 on, Jan 24th, 2025

by: WOPRAI

Jay Olson Downgraded (EXEL) to Perform and Decreased Target to $33 on, Jan 24th, 2025

by: WOPRAI

Jared Shaw Maintained (EWBC) at Overweight with Decreased Target to $120 on, Jan 24th, 2025

by: WOPRAI

Richard Hightower Maintained (ESS) at Equal with Decreased Target to $302 on, Jan 24th, 2025

by: WOPRAI

Richard Hightower Maintained (EQR) at Overweight with Decreased Target to $79 on, Jan 24th, 2025

by: WOPRAI

Jeffrey Bernstein Maintained (EAT) at Equal with Increased Target to $150 on, Jan 24th, 2025

by: WOPRAI

Jeffrey Bernstein Maintained (DPZ) at Underweight with Decreased Target to $402 on, Jan 24th, 2025

by: WOPRAI

Richard Shane Maintained (DFS) at Neutral with Increased Target to $169 on, Jan 24th, 2025

by: WOPRAI

Karl Shepard Maintained (DFS) at Sector with Increased Target to $210 on, Jan 24th, 2025

by: WOPRAI

Wood Lay Maintained (CWBC) at Market with Decreased Target to $22 on, Jan 24th, 2025

by: WOPRAI

Matt Breese Reiterated (CUBI) at Equal and Held Target at $58 on, Jan 24th, 2025

by: WOPRAI

Patrick Brown Reiterated (CSX) at Outperform with Decreased Target to $37 on, Jan 24th, 2025

by: WOPRAI

James McGarragle Maintained (CSX) at Sector with Decreased Target to $33 on, Jan 24th, 2025

by: WOPRAI

Brian Ossenbeck Maintained (CSX) at Overweight with Decreased Target to $37 on, Jan 24th, 2025

by: WOPRAI

Brandon Oglenski Maintained (CSX) at Overweight with Decreased Target to $38 on, Jan 24th, 2025

by: WOPRAI

Benjamin Hartford Maintained (CSX) at Outperform with Decreased Target to $38 on, Jan 24th, 2025

by: WOPRAI

Ariel Rosa Maintained (CSX) at Buy with Decreased Target to $39 on, Jan 24th, 2025

by: WOPRAI

Nathan Jones Maintained (CR) at Hold with Decreased Target to $170 on, Jan 24th, 2025

by: WOPRAI

Richard Hightower Maintained (CPT) at Overweight with Decreased Target to $126 on, Jan 24th, 2025

by: WOPRAI

Lisa Gill Maintained (COR) at Overweight with Increased Target to $301 on, Jan 24th, 2025

by: WOPRAI

Christopher Mcgratty Maintained (COLB) at Market with Decreased Target to $33 on, Jan 24th, 2025

by: WOPRAI

Patrick Scholes Maintained (CCL) at Hold with Increased Target to $30 on, Jan 24th, 2025

by: WOPRAI

Lisa Gill Maintained (CAH) at Neutral with Increased Target to $142 on, Jan 24th, 2025

Altimmune's SWOT analysis: pemvidutide potential drives stock outlook

Altimmune, Inc. (NASDAQ:ALT), a biopharmaceutical company with a market capitalization of $503.56 million focused on developing treatments for liver disease and obesity, has been garnering attention from analysts and investors alike.
The article from MSN Money discusses Altimmune, Inc., a clinical-stage biopharmaceutical company, focusing on its SWOT analysis and the potential impact of its lead product candidate, pemvidutide, on its stock outlook. Pemvidutide is a GLP-1/glucagon dual receptor agonist aimed at treating obesity and non-alcoholic steatohepatitis (NASH). Strengths include a promising pipeline with pemvidutide showing significant weight loss in early trials, and a robust intellectual property portfolio. Weaknesses highlight the company's reliance on the success of pemvidutide, with no other products currently generating revenue, and its history of net losses. Opportunities are vast, given the growing market for obesity and NASH treatments, potential partnerships, and the possibility of expanding into other metabolic diseases. Threats include intense competition from larger pharmaceutical companies, potential clinical trial failures, and regulatory hurdles. The article suggests that while pemvidutide's potential could drive stock value, investors should consider the inherent risks associated with clinical-stage biotech companies.

Read the Full MSN Article at:
https://www.msn.com/en-us/money/general/altimmune-s-swot-analysis-pemvidutide-potential-drives-stock-outlook/ar-AA1xLijY